Celgene to Pay $280 Million to Settle Off-label Marketing Case Celgene to Pay $280 Million to Settle Off-label Marketing Case

The U.S. Justice Department said on Tuesday that Celgene Corp had agreed to pay $280 million to settle a lawsuit that accused the company of promoting its cancer drugs Revlimid and Thalomid for off-label uses.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news